

Amendments to the Claims

1. (Original) An aqueous suspension comprising loteprednol etabonate and at least one member selected from the group consisting of sorbic acid, salts thereof and p-hydroxybenzoic acid esters.

2. (Original) The aqueous suspension according to Claim 1 wherein a non-ionic surfactant is additionally contained.

3. (Currently amended) The aqueous suspension according to Claim 1 ~~or 2~~ wherein the suspension is an eye-drop.

4. (Currently amended) The aqueous suspension according to Claim 1 ~~or 2~~ wherein the suspension is a nasal-drop.

5. (Currently amended) The aqueous suspension according to Claim 1 ~~or 2~~ wherein the suspension is an ear-drop.

6. (Original) A method for improving redispersibility of loteprednol etabonate which comprises compounding at least one member selected from the group consisting of sorbic acid, salts thereof and p-hydroxybenzoic acid esters in an aqueous suspension containing loteprednol etabonate.

7. (New) The aqueous suspension according to Claim 2 wherein the suspension is an eye-drop.

8. (New) The aqueous suspension according to Claim 2 wherein the suspension is a nasal-drop.

9. (New) The aqueous suspension according to Claim 2 wherein the suspension is an ear-drop.